Affimed Nv (AFMD)

$4.88

-0.47

(-8.79%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Affimed Nv

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.96M → 413.0K (in $), with an average decrease of 79.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -31.98M → -20.20M (in $), with an average increase of 16.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 93.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 336.3%

Performance

  • $4.87
    $5.44
    $4.88
    downward going graph

    0.31%

    Downside

    Day's Volatility :10.49%

    Upside

    10.21%

    downward going graph
  • $2.24
    $11.10
    $4.88
    downward going graph

    54.1%

    Downside

    52 Weeks Volatility :79.82%

    Upside

    56.04%

    downward going graph

Returns

PeriodAffimed NvSector (Health Care)Index (Russel 2000)
3 Months
-15.35%
1.7%
0.0%
6 Months
46.77%
11.3%
0.0%
1 Year
-43.39%
5.4%
1.3%
3 Years
-95.71%
13.9%
-22.1%

Highlights

Market Capitalization
76.1M
Book Value
$3.85
Earnings Per Share (EPS)
-7.56
PEG Ratio
0.0
Wall Street Target Price
22.5
Profit Margin
0.0%
Operating Margin TTM
-382.46%
Return On Assets TTM
-43.5%
Return On Equity TTM
-100.55%
Revenue TTM
13.9M
Revenue Per Share TTM
0.93
Quarterly Revenue Growth YOY
-58.3%
Gross Profit TTM
42.9M
EBITDA
-102.6M
Diluted Eps TTM
-7.56
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.22
EPS Estimate Next Year
-3.77
EPS Estimate Current Quarter
-1.67
EPS Estimate Next Quarter
-1.44

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Affimed Nv(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 361.07%

Current $4.88
Target $22.50

Company Financials

FY18Y/Y Change
Revenue
27.2M
↑ 1080.85%
Net Income
-22.3M
↓ 35.56%
Net Profit Margin
-82.06%
↑ 1421.57%
FY19Y/Y Change
Revenue
24.0M
↓ 9.88%
Net Income
-36.3M
↑ 66.17%
Net Profit Margin
-151.3%
↓ 69.24%
FY20Y/Y Change
Revenue
34.9M
↑ 32.58%
Net Income
-50.9M
↑ 27.81%
Net Profit Margin
-145.86%
↑ 5.44%
FY21Y/Y Change
Revenue
45.7M
↑ 42.33%
Net Income
-65.1M
↑ 39.06%
Net Profit Margin
-142.5%
↑ 3.36%
FY22Y/Y Change
Revenue
44.3M
↑ 2.45%
Net Income
-92.1M
↑ 49.51%
Net Profit Margin
-207.98%
↓ 65.48%
FY23Y/Y Change
Revenue
8.3M
↓ 79.99%
Net Income
-105.9M
↑ 23.18%
Net Profit Margin
-1.3K%
↓ 1072.24%
Q3 FY22Q/Q Change
Revenue
14.6M
↑ 103.92%
Net Income
-13.5M
↓ 19.73%
Net Profit Margin
-92.5%
↑ 142.48%
Q4 FY22Q/Q Change
Revenue
4.8M
↓ 69.71%
Net Income
-34.3M
↑ 132.25%
Net Profit Margin
-709.16%
↓ 616.66%
Q1 FY23Q/Q Change
Revenue
4.9M
↑ 0.0%
Net Income
-34.9M
↑ 0.0%
Net Profit Margin
-709.16%
↑ 0.0%
Q2 FY23Q/Q Change
Revenue
1.5M
↓ 69.18%
Net Income
-32.1M
↓ 8.09%
Net Profit Margin
-2.1K%
↓ 1405.59%
Q3 FY23Q/Q Change
Revenue
2.0M
↑ 41.15%
Net Income
-24.4M
↓ 17.15%
Net Profit Margin
-1.2K%
↑ 873.41%
Q4 FY23Q/Q Change
Revenue
413.0K
↓ 78.95%
Net Income
-20.2M
↓ 17.04%
Net Profit Margin
-4.9K%
↓ 3650.91%
FY18Y/Y Change
Total Assets
132.9M
↑ 169.18%
Total Liabilities
87.0M
↑ 556.75%
FY19Y/Y Change
Total Assets
125.9M
↓ 3.28%
Total Liabilities
82.5M
↓ 3.09%
FY20Y/Y Change
Total Assets
216.1M
↑ 56.4%
Total Liabilities
127.6M
↑ 40.76%
FY21Y/Y Change
Total Assets
255.0M
↑ 28.12%
Total Liabilities
101.0M
↓ 14.02%
FY22Y/Y Change
Total Assets
214.8M
↓ 10.94%
Total Liabilities
51.0M
↓ 46.63%
FY23Y/Y Change
Total Assets
97.2M
↓ 51.55%
Total Liabilities
39.4M
↓ 17.33%
Q3 FY22Q/Q Change
Total Assets
232.4M
↓ 9.39%
Total Liabilities
54.4M
↓ 18.78%
Q4 FY22Q/Q Change
Total Assets
179.9M
↓ 28.95%
Total Liabilities
45.9M
↓ 22.48%
Q1 FY23Q/Q Change
Total Assets
183.2M
↑ 0.0%
Total Liabilities
46.7M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
147.0M
↓ 19.79%
Total Liabilities
39.0M
↓ 16.52%
Q3 FY23Q/Q Change
Total Assets
120.5M
↓ 10.58%
Total Liabilities
44.0M
↑ 23.08%
Q4 FY23Q/Q Change
Total Assets
97.2M
↓ 19.35%
Total Liabilities
39.4M
↓ 10.66%
FY18Y/Y Change
Operating Cash Flow
56.6M
↓ 293.5%
Investing Cash Flow
-17.9M
↓ 293.91%
Financing Cash Flow
23.4M
↓ 13.88%
FY19Y/Y Change
Operating Cash Flow
-32.5M
↓ 158.77%
Investing Cash Flow
4.9M
↓ 127.8%
Financing Cash Flow
29.2M
↑ 27.05%
FY20Y/Y Change
Operating Cash Flow
-23.9M
↓ 33.23%
Investing Cash Flow
9.8M
↑ 84.47%
Financing Cash Flow
85.2M
↑ 165.97%
FY21Y/Y Change
Operating Cash Flow
-98.1M
↑ 346.35%
Investing Cash Flow
-4.4M
↓ 148.09%
Financing Cash Flow
151.3M
↑ 92.89%
Q3 FY22Q/Q Change
Operating Cash Flow
-18.7M
↓ 28.15%
Investing Cash Flow
2.1M
↑ 50.7%
Financing Cash Flow
-465.9K
↓ 100.53%
Q4 FY22Q/Q Change
Operating Cash Flow
-35.6M
↑ 74.71%
Investing Cash Flow
-3.2K
↓ 100.14%
Financing Cash Flow
-679.2K
↑ 33.76%
Q1 FY23Q/Q Change
Operating Cash Flow
-36.3M
↑ 0.0%
Investing Cash Flow
-3.3K
↑ 0.0%
Financing Cash Flow
-691.4K
↑ 0.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-36.4M
↑ 0.26%
Investing Cash Flow
-3.3K
↑ 0.0%
Financing Cash Flow
-2.8M
↑ 306.94%
Q3 FY23Q/Q Change
Operating Cash Flow
-18.3M
↓ 45.24%
Investing Cash Flow
-37.5M
↑ 1248400.0%
Financing Cash Flow
-1.6M
↓ 37.6%

Technicals Summary

Sell

Neutral

Buy

Affimed Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Affimed Nv
Affimed Nv
-5.97%
46.77%
-43.39%
-95.71%
-85.3%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Affimed Nv
Affimed Nv
NA
NA
0.0
-5.22
-1.01
-0.43
NA
3.85
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Affimed Nv
Affimed Nv
Buy
$76.1M
-85.3%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • 683 Capital Management LLC

    4.69%

  • NEA Management Company, LLC

    2.96%

  • Point72 Asset Management, L.P.

    2.83%

  • Millennium Management LLC

    1.37%

  • Eversept Partners, LLC

    1.12%

  • Morgan Stanley - Brokerage Accounts

    0.96%

Corporate Announcements

  • Affimed Nv Earnings

    Affimed Nv’s price-to-earnings ratio stands at None

    Read More

Company Information

affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli

Organization
Affimed Nv
Employees
76
CEO
Dr. Andreas Harstrick M.D.
Industry
Health Technology

Discover More

FAQs